Clinical Trial Update: Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, antiviral activity, and pharmacokinetics of GSK2336805 in combination with peginterferon and ribavirin in chronic hepatitis C s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GSK2336805
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2017-12-11